

| May 18, 2022                              |                            |
|---|----------------------------|
| National Stock Exchange of India Limited, | BSE Limited,               |
| Listing Compliance Department             | Listing Department,        |
| Exchange Plaza, C-1, Block G,             | Phiroze Jeejeebhoy Towers, |
| Bandra Kurla Complex,                     | Dalal Street,              |
| Bandra (East)                             | Mumbai- 400001             |
| Mumbai – 400 051                          |                            |
| Scrip Symbol: GALAXYSURF                  | Scrip Code: 540935         |

#### Sub: Investor presentation on the audited financial results for the quarter ended March 31, 2022.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation on the audited financial results for the quarter ended March 31, 2022.

The information is also hosted in announcement section on the website of the Company at <u>www.galaxysurfactants.com</u>.

We request you to take the same on record.

Yours faithfully, For Galaxy Surfactants Limited

Niranjan Ketkar Company Secretary M. No. A20002 encl: as above

#### **Communication Address:**

Rupa Solitaire, Ground Floor, Unit no. 8, 12A and 14 Millennium Business Park, Mahape, Navi Mumbai, 400 710 Ph: +91-22-33063700 Regd. Office: C-49/2, TTC Industrial Area, Pawne, Navi Mumbai-400 703, India CIN: L39877MH1986PLC039877 Ph: +91-22-27616666 Fax : +91-22-27615883/ 27615886 e-mail : galaxy@galaxysurfactants.com Website: www.galaxysurfactants.com





# Galaxy Surfactants Limited

Investor Presentation - May 2022









This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.





# Q4 & FY22 Performance Highlights



U Shaped recovery with a robust Q4 performance

Better Mix, Realizations & Recoveries aid EBITDA/MT

Demand cutbacks & downtrading in AMET adversely impacted Performance Surfactants Volumes

Normalcy & opening up of developed markets aids growth of Specialty Care portfolio


Russia-Ukraine war & China induced lockdowns exacerbate supply-led volatility





## Volume: Q4FY22 Highlights

**Performance Surfactants** 










**Total Volume** 

India Market grew YoY by 3.3%



Africa Middle East Turkey de-grew YoY by 29.1%










**Responsible Care** 

**Volume Highlights** 

## Volume: FY22 Highlights










Rest of the World grew by 7.8%





## Q4FY22 & FY22 Consolidated Highlights





^Includes other Income

**Responsible Care** 

## Consolidated Profit & Loss Statement

| U          | Ga        | rla.   | хy     |
|------------|-----------|--------|--------|
| Global Sup | pplier to | Global | Brands |

| Particulars (Rs. In Crores) | Q4FY22  | Q4FY21 | Y-o-Y | Q3FY22 | Q-o-Q | FY22             | FY21    | Y-o-Y |
|-----------------------------|---------|--------|-------|--------|-------|------------------|---------|-------|
| Net Revenue from Operations | 1,052.9 | 783.5  | 34%   | 929.1  | 13%   | 3 <i>,</i> 685.7 | 2,784.1 | 32%   |
| Other Income                | 1.2     | 2.6    |       | 1.8    |       | 12.5             | 10.9    |       |
| Total Revenue               | 1,054.1 | 786.1  | 34%   | 930.9  | 13%   | 3,698.2          | 2,794.9 | 32%   |
| Cost of Material Consumed   | 705.8   | 497.2  |       | 674.1  |       | 2,588.5          | 1,774.6 |       |
| Employee's Benefits Expense | 58.3    | 58.9   |       | 51.6   |       | 211.8            | 204.0   |       |
| Other Expenses              | 143.9   | 110.0  |       | 127.1  |       | 484.7            | 356.6   |       |
| EBITDA                      | 146.2   | 120.0  | 22%   | 78.2   | 87%   | 413.2            | 459.7   | -10%  |
| EBITDA Margin               | 13.9%   | 15.3%  |       | 8.4%   |       | 11.2%            | 16.4%   |       |
| Depreciation                | 18.4    | 24.0   |       | 17.7   |       | 71.1             | 74.0    |       |
| EBIT                        | 127.8   | 96.0   | 33%   | 60.4   | 112%  | 342.2            | 385.7   | -11%  |
| Finance cost                | 3.4     | 3.0    |       | 2.8    |       | 12.9             | 13.4    |       |
| PBT                         | 124.4   | 93.0   | 34%   | 57.6   | 116%  | 329.3            | 372.3   | -12%  |
| Tax expense                 | 26.0    | 14.3   |       | 12.0   |       | 66.5             | 70.2    |       |
| PAT                         | 98.4    | 78.7   | 25%   | 45.6   | 116%  | 262.8            | 302.1   | -13%  |
| PAT Margin                  | 9.3%    | 10.0%  |       | 4.9%   |       | 7.1%             | 10.8%   |       |
| Other Comprehensive Income  | 15.0    | -1.3   |       | 1.2    |       | 24.3             | -18.8   |       |
| Total Comprehensive Income  | 113.4   | 77.4   | 46%   | 46.8   | 142%  | 287.1            | 283.3   | 1%    |
| EPS                         | 27.76   | 22.19  |       | 12.86  |       | 74.12            | 85.22   |       |

Fatty Alcohol prices in this Quarter increased to an average price of \$ 2,862/MT vs, average prices of \$ 2,073/MT in Q4FY21. The same was \$ 2,602/MT in Q3FY22



### Consolidated Balance Sheet



| Particulars (Rs. In Crores)                             | Mar'22  | Mar'21  |
|---|---------|---------|
| ASSETS  |         |         |
| Property, Plant and Equipment                           | 609.2   | 591.7   |
| Right-of-use assets                                     | 143.0   | 111.9   |
| Capital work-in-progress                                | 205.5   | 124.0   |
| Goodwill  | 2.8     | 2.7     |
| Other Intangible Assets                                 | 5.4     | 5.7     |
| Financial Assets  |         |         |
| (i) Loans   | 0.4     | 0.3     |
| (ii) Other financial assets                             | 11.1    | 8.9     |
| Deferred Tax Assets (Net)                               | 3.9     | 0.7     |
| Income Tax Assets (Net)                                 | 8.5     | 11.2    |
| Other Non-current tax assets                            | 40.5    | 35.0    |
| Total Non-Current Assets                                | 1,030.4 | 891.8   |
| Current Assets  |         |         |
| Inventories   | 711.8   | 427.8   |
| Financial Assets  |         |         |
| (i) Investments   | 0.5     | 43.5    |
| (ii) Trade receivables                                  | 638.0   | 468.9   |
| (iii) Cash and cash equivalents                         | 63.8    | 81.5    |
| (iv) Bank Balances other than cash and cash equivalents | 7.4     | 29.9    |
| (v) Loans   | 0.5     | 0.3     |
| (vi) Other Financial Assets                             | 7.2     | 5.9     |
| Other Current Assets                                    | 141.2   | 99.9    |
| Total Current Assets                                    | 1,570.2 | 1,157.7 |
| TOTAL ASSETS  | 2,600.6 | 2,049.5 |

| Particulars (Rs. In Crores)       | Mar'22  | Mar'21  |
|-----------------------------------|---------|---------|
| EQUITY AND LIABILITIES            |         |         |
| EQUITY                            |         |         |
| Equity Share Capital              | 35.5    | 35.5    |
| Other Equity                      | 1,538.9 | 1,266.0 |
| Total Shareholders Fund           | 1,574.4 | 1,301.4 |
|                                   |         |         |
| Non-Current Liabilities           |         |         |
| Financial Liabilities             |         |         |
| (i) Borrowings                    | 79.6    | 77.4    |
| (ii) Lease Liabilities            | 48.4    | 16.9    |
| (iii) Other Financial Liabilities | 0.3     | 0.4     |
| Provisions                        | 7.6     | 10.1    |
| Deferred Tax Liabilities (Net)    | 24.9    | 23.3    |
| Other non-current liabilities     | 0.0     | 0.0     |
| Total Non-Current Liabilities     | 160.8   | 128.0   |
|                                   |         |         |
| Current Liabilities               |         |         |
| Financial Liabilities             |         |         |
| (i) Borrowings                    | 286.4   | 190.6   |
| (ii) Trade Payables               | 518.9   | 377.0   |
| (iii) Lease Liabilities           | 6.4     | 4.4     |
| (iv) Other Financial Liabilities  | 5.6     | 5.4     |
| Other Current Liabilities         | 32.7    | 33.0    |
| Provisions                        | 7.7     | 8.6     |
| Current Tax Liabilities (Net)     | 7.8     | 1.2     |
| Total Current Liabilities         | 865.4   | 620.1   |
| TOTAL EQUITY & LIABILITIES        | 2,600.6 | 2,049.5 |



## **Consolidated Cash Flow**



|   | Full Yea | Full Year ended |  |
|---|----------|-----------------|--|
| Particulars (Rs. In Crores)   | Mar'22   | Mar'21          |  |
| Cash Flow From Operating Activities :   |          |                 |  |
| Profit After Tax  | 262.8    | 302.1           |  |
| Operating Profit before working Capital changes   | 409.4    | 454.2           |  |
| Net cash flows generated from/(used) in Operating Activities (A)  | 4.9      | 365.1           |  |
| Net cash flows generated from/(used) in Investing Activities (B)  | (84.1)   | (164.7)         |  |
| Net cash flows generated from/(used) in Financing Activities (C)  | 59.2     | (165.0)         |  |
| Net Increase/(Decrease) in cash and cash equivalents (A+B+C)  | (20.0)   | 35.4            |  |
| Opening cash and cash equivalents   | 81.5     | 47.7            |  |
| Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies | 2.3      | (1.6)           |  |
| Closing cash and cash equivalents   | 63.8     | 81.5            |  |



### Standalone Profit & Loss Statement



| Particulars (Rs. In Crores) | Q4FY22 | Q4FY21 | Y-o-Y         | Q3FY22 | Q-o-Q | FY22    | FY21    | Y-o-Y |
|-----------------------------|--------|--------|---------------|--------|-------|---------|---------|-------|
| Net Revenue from Operations | 792.7  | 526.8  | 50%           | 656.4  | 21%   | 2,628.6 | 1,830.5 | 44%   |
| Other Income                | -17.6  | 1.8    | 4.9           |        |       | -1.2    | 4.4     |       |
| Total Revenue               | 775.2  | 528.6  | 47% 661.3 17% |        | 17%   | 2,627.4 | 1,834.9 | 43%   |
| Cost of Material Consumed   | 570.6  | 352.9  |               | 497.5  |       | 1,949.3 | 1,208.1 |       |
| Employee's Benefits Expense | 32.3   | 31.3   |               | 28.1   |       | 113.6   | 105.7   |       |
| Other Expenses              | 100.9  | 70.9   |               | 90.1   |       | 331.9   | 223.7   |       |
| EBITDA                      | 71.4   | 73.5   | -3%           | 45.7   | 56%   | 232.5   | 297.5   | -22%  |
| EBITDA Margin               | 9.2%   | 13.9%  |               | 6.9%   |       | 8.9%    | 16.2%   |       |
| Depreciation                | 11.2   | 18.1   |               | 10.9   |       | 43.8    | 49.8    |       |
| EBIT                        | 60.2   | 55.5   | 9%            | 34.8   | 73%   | 188.8   | 247.7   | -24%  |
| Finance cost                | 2.0    | 2.1    |               | 1.6    |       | 7.8     | 8.4     |       |
| PBT                         | 58.2   | 53.4   | <b>9%</b>     | 33.2   | 75%   | 181.0   | 239.3   | -24%  |
| Tax expense                 | 15.6   | 14.0   |               | 8.8    |       | 47.2    | 61.5    |       |
| PAT                         | 42.6   | 39.4   | 8%            | 24.5   | 74%   | 133.9   | 177.9   | -25%  |
| PAT Margin                  | 5.5%   | 7.5%   | 3.7%          |        |       | 5.1%    | 9.7%    |       |
| Other Comprehensive Income  | 1.4    | -1.8   |               | -0.1   |       | 1.2     | -1.2    |       |
| Total Comprehensive Income  | 44.0   | 37.6   | 17%           | 24.4   | 80%   | 135.1   | 176.6   | -24%  |
| EPS                         | 12.02  | 11.12  |               | 6.90   |       | 37.76   | 50.17   |       |



### Standalone Balance Sheet



| Particulars (Rs. In Crores)                              | Mar'22  | Mar'21  |
|--|---------|---------|
| ASSETS   |         |         |
| Property, Plant and Equipment                            | 383.8   | 358.5   |
| Right-of-use assets                                      | 98.5    | 99.2    |
| Capital work-in-progress                                 | 178.2   | 116.2   |
| Goodwill   | -       | -       |
| Other Intangible Assets                                  | 5.3     | 5.6     |
| Financial Assets   |         |         |
| (i) Investments  | 208.2   | 216.7   |
| (ii) Loans   | 0.4     | 0.3     |
| (iii) Other financial assets                             | 6.6     | 5.6     |
| Deferred Tax Assets (Net)                                | 0.0     | 0.0     |
| Income Tax Assets (Net)                                  | 8.5     | 8.0     |
| Other Non-current tax assets                             | 22.3    | 28.6    |
| Total Non-Current Assets                                 | 911.8   | 838.7   |
| Current Assets   |         |         |
| Inventories  | 409.5   | 270.2   |
| Financial Assets   |         |         |
| (i) Trade receivables                                    | 474.7   | 339.6   |
| (ii) Cash and cash equivalents                           | 8.2     | 11.9    |
| (iii) Bank Balances other than cash and cash equivalents | 5.8     | 12.9    |
| (iv) Loans   | 0.4     | 0.3     |
| (v) Other Financial Assets                               | 7.5     | 6.0     |
| Other Current Assets                                     | 61.8    | 78.1    |
| Total Current Assets                                     | 967.7   | 718.9   |
| TOTAL ASSETS   | 1,879.5 | 1,557.6 |

| Particulars (Rs. In Crores)       | Mar'22  | Mar'21  |
|-----------------------------------|---------|---------|
| EQUITY AND LIABILITIES            |         |         |
| EQUITY                            |         |         |
| Equity Share Capital              | 35.5    | 35.5    |
| Other Equity                      | 1,102.2 | 981.4   |
| Total Shareholders Fund           | 1,137.7 | 1,016.8 |
|                                   |         |         |
| Non-Current Liabilities           |         |         |
| Financial Liabilities             |         |         |
| (i) Borrowings                    | 62.8    | 53.0    |
| (ii) Lease Liabilities            | 4.8     | 4.8     |
| (iii) Other Financial Liabilities | 0.3     | 0.4     |
| Provisions                        | 7.6     | 10.1    |
| Deferred Tax Liabilities (Net)    | 29.1    | 29.3    |
| Other non-current liabilities     | -       | -       |
| Total Non-Current Liabilities     | 104.6   | 97.5    |
| Current Liabilities               |         |         |
| Financial Liabilities             |         |         |
| (i) Borrowings                    | 186.7   | 110.8   |
| (ii) Trade Payables               | 419.0   | 306.5   |
| (iii) Lease Liabilities           | 3.0     | 2.7     |
| (iv) Other Financial Liabilities  | 4.3     | 4.0     |
| Other Current Liabilities         | 16.7    | 12.8    |
| Provisions                        | 5.3     | 5.2     |
| Current Tax Liabilities (Net)     | 2.2     | 1.2     |
| Total Current Liabilities         | 637.3   | 443.2   |
| TOTAL EQUITY & LIABILITIES        | 1,879.5 | 1,557.6 |



### Standalone Cash Flow



|   | Full Yea | Full Year ended |  |
|---|----------|-----------------|--|
| Particulars (Rs. In Crores)   | Mar'22   | Mar'21          |  |
| Cash Flow From Operating Activities :   |          |                 |  |
| Profit After Tax  | 133.9    | 177.9           |  |
| Operating Profit before working Capital changes   | 239.6    | 296.5           |  |
| Net cash flows generated from/(used) in Operating Activities (A)  | 46.2     | 183.7           |  |
| Net cash flows generated from/(used) in Investing Activities (B)  | (108.7)  | (104.5)         |  |
| Net cash flows generated from/(used) in Financing Activities (C)  | 58.7     | (84.2)          |  |
| Net Increase/(Decrease) in cash and cash equivalents (A+B+C)  | (3.8)    | (5.0)           |  |
| Opening cash and cash equivalents   | 11.9     | 16.9            |  |
| Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies | 0.0      | 0.0             |  |
| Closing cash and cash equivalents   | 8.1      | 11.9            |  |




# **Business Overview**



## Truly Indian MNC...





## ...Vertically Integrated in HPC Industry







India's Largest Manufacturer of Oleochemical based Surfactants and Speciality Care Products for Home Care and Personal Care Industries (HPC) Consumer to Innovation & Chemistry Technology 05 03 01 02 **Global Supplier** 04 Multiple High Growth to Global Brands Products across Industry Categories



## Our growth trajectory over Three Decades



Revenue (Rs in Crores) 2004: setting up of EOU at Taloja **2011:** Commissioning of Egypt and Jhagadia Plants 1986: Incorporation of Company 1994: New plant set up at Tarapur 2014: Purchase of business of Surfactants 1984: New Plant at Tarapur for 1995: Acquisition of Galaxy Chemicals 2009: Ethoxylates, Phenoxyethanol, Sunscreens International LLC 1997: Sulfonation plant Setup at Taloja and • Acquisition of Tri-K Industries 2016: Expansion of Jhagadia Plant for mild Research Centre at Navi Mumbai • Galaxy Chemicals Egypt S.A.E. & surfactants 1998: Commissioning of new plant in Taloja Rainbow Holdings GmbH became step down subsidiary 3698 2795 2768 2.602 1696 1801 1317 589 382 322 162 1980 1984 1988 1990 1992 1994 1998 2000 2004 2007 2008 2010 2012 2020 2021 2022 2014 2016 2019 2010 - 2022 1980-1990 1990-2000 2000-2010 IMPORT SUBSTITUTION GLOBAL ESTABLISHMENT **INDIA GROWTH PHASE** EXPORT GROWTH PHASE Dominant Share in India Post Economic Liberalisation, market for Strategic shift with focus on Global Established credentials in surfactants/ Increased Global Participations personal care products grew substantially specialty ingredients space markets expansion Supplier Recognitions (Global) Galaxy emerged as a strong player Due to high import duties, personal care Made investments to acquire products were considered luxury goods manufacturing facilities at USA, Egypt Strong R&D Capability Grew exponentially led by strong Galaxy was a strong supplier for import and established international offices innovation capabilities Customer Partnership substitution Increased share of revenue from Focused on capturing the domestic market IPO – listing of the company on BSE and NSE Developed a solid R&D base international business and large customer accounts Set up capacities to cater to the emerging Accepted as Global Vendor benchmarked requirements with best International peers



### **Our focus is Personal & Home Care Segment**

Responsible Care®





## ... with over 220+ Product Offerings



| Performance                                      | Anionic Surfactants                                      |  | FAES, FAS, LABSA   |                   | Foam and Dirt removal properties   |
|--|--|--|--|-------------------|--|
| Surfactants                                      | Actants Non-Ionics Surfactants                           |  | Ethoxylates  |                   | <ul> <li>Cosmetics and Personal care products as emulsifiers and solubilisers</li> </ul>   |
|  | Amphoteric Surfactants                                   |  | Betaines   |                   | <ul> <li>Dermatological properties to reduces skin irritation</li> </ul>   |
|  | Cationic Surfactants                                     |  | Quats  | fits              | <ul> <li>Effective conditioning aids: substantively to hair and antimicrobial properties</li> </ul>  |
|  | UV Filters   |  | Sunscreen Agents<br>(OMC, OCN &Others)   | Consumer Benefits | Absorb or block the harmful radiation, Mild for the skin with Moisturizing   |
| Speciality Care<br>Products                      | Preservatives,<br>Preservative Blends                    |  | Phenoxyethanol, Preservative Blends  | Consur            | Reduced toxicity & prevent spoilage  |
|  | Speciality Ingredients                                   |  | Mild Surfactants (MS), Proteins and<br>Syndet & Transparent Bathing Bar<br>Flakes, Surfactant Blends |                   | <ul> <li>MS: Cleanse adequately without compromising basic function of skin</li> <li>Protein: cosmetic industry for conditioning, protection and strengthening of hair/skin, anti-irritancy, moisturization etc</li> </ul> |
| Bifurcation is only for<br>Investor community as | Fatty Alkanolamides (FA) and<br>Fatty Acid Easters (FAE) |  |  |                   | ✓ FA & FAE: Foam, viscosity boosters and pearlizer in a formulation  |
| every product has different functionality        | Other Care Products                                      |  | Conditioning Agents, Polyquats &<br>Amine Oxides   |                   | Improves the quality of another material also called as moisturizers, conditioning benefits to the hair etc  |

### Our Business Segments...



### **Performance Surfactants**

"Substantive Raw Material in Customer's End-products"

- Products are functional in nature where Endconsumer require foaming & cleansing
- Large volume consumption in all rinse-off formulations
- Products are Pulled by FMCG as it is required due to impulse buying from end consumer

### **Speciality Care Products**

"Unique Functionality to Customer's End-products"

- Niche & Premium products
- Low volume consumption
- Oligopolistic for most products
- Low penetration due to its unique application



**39**%

### **About Product**








#### Revenue Mix (FY22)





### **Our Global Footprints**






Presence in High Growth & Matured Markets





### "Consumer to Chemistry": Creation of Products





Collaborative product development with Customers which helps Customers in choosing "**Right Technology** with Right Application"

Inhouse R&D Team of 74 professionals comprising of doctorates, chemists and engineers

Well-Equipped R&D Centre, Pilot Plant at Tarapur, Maharashtra; Product applications centre for proteins at Denville, USA


Innovation Funnel (adopted in 2007) to consistently diversify product offerings, meet customer needs and consumer trends





## State-of-the-art Manufacturing Facilities






\*Environmental clearances for expansion and additional land available at Jhagadia and Suez plants



### 1,450+ Clients across 80+ Countries





## Awards & Certifications: Won in the Past Decade





"Great Place to Work" for the Fiscal 2017-2018



"Silver Medal" in India Green Manufacturing Challenge 2016 for Jhagadia unit

"Certificate of Appreciation" in occupational safety & health by National Safety Council of India for Taloja Plant, 2011

"Special Award for TPM Achievement", 2008

"Certificate of Merit 2008 -Manufacturing Category" in the IMC Ramkrishna Bajaj National Quality Award 2008"



### Accolades Received in FY22













# Galaxy Surfactants Ltd. has been certified as 1.4X water positive

Because businesses thrive only when communities thrive



Commemorating World Water Day, 2022, Galaxy Surfactants emerged as among the few Indian companies to achieve water positive certification and become 1.4X water positive

The certification was granted by DNV Business Assurance India Private Limited which carried out verification of Galaxy's Water Accounting Data for its operational plants at Tarapur, Taloja and Jhagadia and Corporate Office at Navi Mumbai in India

From January '21 to December '21, Galaxy Surfactants restored 4,15,261 (CuM) cubic metres of water back to the environment in comparison to its withdrawal of 2,97,513 CuM of water

Galaxy Surfactants, with the principles of Water Stewardship, has directed its operations to ensure the usage of water, socially and culturally equitable, environmentally sustainable, and economically beneficial.

DNV adopted a risk-based approach and conducted the onsite and off-site evaluation of the qualitative and quantitative information and Water Debit and Credit data presented in Galaxy Surfactants' Water Report



### Management Team on Board





### Mr. Melarkode G. Parameswaran Chairman

Appointed as Chairman w.e.f. 20<sup>th</sup> April, 2022
Associated with Company since 2005
Chemical Engineer from IIT Madras; PGDM from IIM Calcutta; PhD from Mumbai University



Mr. Unnathan Shekhar Promoter, Managing Director

Associated with Company since 1986Chemical Engineer, PGDM from IIM, Calcutta



- Mr. Natarajan K. Krishnan Executive Director, Chief Operating Officer
- Associated with Company since 1993
  CWA, Advanced Management Program from Harvard Business School



Mr. Kasargod Ganesh Kamath Executive Director (Finance), Chief Financial Officer

Associated with Company since 2004
Qualified CS, CWA and LL.B, over 20 years of experience



### Mr. Vaijanath Kulkarni Whole Time Director(WTD)

- Associated with Company since 1995Chemical Engineer
- •Appointed as Whole Time Director in Galaxy Surfactants w.e.f. 16<sup>th</sup> October, 2021







Mr. Gopalkrishnan Ramakrishnan Promoter, Non-Executive Director

Associated with Company since 1986Qualified CA and CS



Mr. Shashikant R. Shanbhag Promoter, Non-Executive Director

Associated with Company since1986Qualified CA



Mr. Subodh S. Nadkarni Non-Executive Independent Director

Associated with Company since
2002, 30 years+ experience
Qualified CA and CS, prior
associations with Godrej and Sulzer



Ms. Nandita Gurjar Non-Executive Independent Director

•Associated with Company since 2015 •Over 20 years of experience in the field of IT and Human Resource



### The 4 Cs: Our Core Strength





Transparent & Open, Respect & Value People, Dreaming & Envisioning, Conducting Business with Integrity



### COMPETENCE

Talented Team which proactively meets Complex & Changing Business Needs



Adhering to Global Quality

Standards, Supplying Customers Globally, Agile & Nimble Footedness



### COMFORT

Respecting our Commitments, Consistent Performance over the years of Timely Delivery & Quality Consistency






# Growth Strategy


## Personal & Home Care: High Entry Barrier Businesses















# Financial Performance






... through Robust Risk Management Practices



### Our Performance Highlights







Responsible Care

^Includes other Income





Cash Flow from Operating Activities (Rs in Crs)



Return on Equity (%)











# Thank You

**Company**:



CIN No: L39877MH1986PLC039877

Mr. Paritosh Srivastava Email: <u>Paritosh.Srivastava@galaxysurfactants.com</u>

www.galaxysurfactants.com

**Investor Relations Advisors :** 



CIN - U74140MH2010PTC204285

Mr. Rahul Agarwal / Ms. Khushbu Shah <u>rahul.agarwal@sgapl.net</u> / <u>khushbu.shah@sgapl.net</u> +91 98214 38864 / +91 9820601181

www.sgapl.net

